,Date,Study,Study Link,Journal,Study Type,Detection Method,Sample Size,Measure of Testing Accuracy,Speed of assay,FDA approval (Y/N),Added on
0,2020-04-10,Evaluation of nine commercial SARS-CoV-2 immunoassays,https://www.medrxiv.org/content/10.1101/2020.04.09.20056325v1,medRxiv,Retrospective Cohort,Wantai SARS-CoV-2 Total Antibody ELISA,30,specifity: 100%; sensitivity: 90%,2 hrs,Y,2020-04-25
1,2020-04-10,Evaluation of nine commercial SARS-CoV-2 immunoassays,https://www.medrxiv.org/content/10.1101/2020.04.09.20056325v1,medRxiv,Retrospective Cohort,Euroimmun IgA ELISA,30,specifity: 93%; sensitivity: 90%,2 hrs,Y,2020-04-25
2,2020-04-10,Evaluation of nine commercial SARS-CoV-2 immunoassays,https://www.medrxiv.org/content/10.1101/2020.04.09.20056325v1,medRxiv,Retrospective Cohort,Euroimmun IgG ELISA,30,specifity: 96; sensitivity: 65%,2 hrs,Y,2020-04-25
3,2020-04-10,Evaluation of nine commercial SARS-CoV-2 immunoassays,https://www.medrxiv.org/content/10.1101/2020.04.09.20056325v1,medRxiv,Retrospective Cohort,Lateral Flow Assay,30,-,2 hrs,Y,2020-04-25
4,2020-03-24,Diagnosing COVID-19: The Disease and Tools for Detection,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7144809/,American Chemical Society,Review,Lateral Flow Antigen Detection,-,"The lateral flow assay has demonstrated a clinical sensitivity, specificity, and accuracy of 57%, 100%, and 69% for IgM and 81%, 100%, and 86% for IgG, respectively. A test that detects both IgM and IgG yields a clinical sensitivity of 82%. [Microfluidics] showed 100% and 87% clinical sensitivity and specificity for HIV",1+ hours,Y,2020-04-25
5,2020-03-24,Diagnosing COVID-19: The Disease and Tools for Detection,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7144809/,American Chemical Society,Review,Microfluidic Devices,-,"The lateral flow assay has demonstrated a clinical sensitivity, specificity, and accuracy of 57%, 100%, and 69% for IgM and 81%, 100%, and 86% for IgG, respectively. A test that detects both IgM and IgG yields a clinical sensitivity of 82%. [Microfluidics] showed 100% and 87% clinical sensitivity and specificity for HIV",1+ hours,Y,2020-04-25
6,2020-03-01,Pixelated colorimetric nucleic acid assay,https://www.sciencedirect.com/science/article/pii/S0039914019312147?via%3Dihub,Talanta,Simulation Study,Pixelated colorimetric nucleic acid assay,-,"Successful detection of HBV DNA was demonstrated in plasma, mimicking clinical samples, with a detection limit of 1 nM.",5-45 minutes,N,2020-04-25
7,2020-02-26,2019 Novel Coronavirus Disease (COVID-19): Paving the Road for Rapid Detection and Point-of-Care Diagnostics,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7142866/,Micromachines,Review,Serology,-,"RT-LAMP Sensitivity >95%; PCR Diagnostic sensitivity of 95%, Sensitivity of Serology 88.66%",RT-LAMP <1 hr; PCR 2-3 days;,Y,2020-04-25
8,2/16/2020,"A  Single and Two-Stage, Closed-Tube, Molecular Test for the 2019  Novel Coronavirus (COVID-19)at Home, Clinic, and Points of Entry",https://chemrxiv.org/articles/A_Single_and_Two-Stage_Closed-Tube_Molecular_Test_for_the_2019_Novel_Coronavirus_COVID-19_at_Home_Clinic_and_Points_of_Entry/11860138,ChemRxiv,Investigative Study,Penn-RAMP,-,COVID-19 Closed-Tube Penn-RAMP provided 100% Sensitivity,<1 Hour,N,2020-04-25
9,2020-02-25,Laboratory diagnosis of emerging human coronavirus infections – the state of the art,https://www.ncbi.nlm.nih.gov/pubmed/32196430,Emerging Microbes & Infections ,Investigative Study,Antigen EIA; ,406,"Rapid, poor sensitivity, some are CLIA-waived; Good sensitivity and specificity, subjective interpretation; Gold standard, pure culture for further research and development, time consuming; Retrospective, cross-reaction; ; High sensitivity and specificity for special species, potential quantification; High sensitivity and specificity, covering other pathogens, FilmArray RP EZ is CLIA-waived; Rapid and safe, good sensitivity and specificity, some are CLIA-waived",<30 min; ,Y,2020-04-25
10,2020-02-25,Laboratory diagnosis of emerging human coronavirus infections – the state of the art,https://www.ncbi.nlm.nih.gov/pubmed/32196430,Emerging Microbes & Infections ,Investigative Study,Antigen IFA,406,"Rapid, poor sensitivity, some are CLIA-waived; Good sensitivity and specificity, subjective interpretation; Gold standard, pure culture for further research and development, time consuming; Retrospective, cross-reaction; ; High sensitivity and specificity for special species, potential quantification; High sensitivity and specificity, covering other pathogens, FilmArray RP EZ is CLIA-waived; Rapid and safe, good sensitivity and specificity, some are CLIA-waived",1–4 h,Y,2020-04-25
11,2020-02-25,Laboratory diagnosis of emerging human coronavirus infections – the state of the art,https://www.ncbi.nlm.nih.gov/pubmed/32196430,Emerging Microbes & Infections ,Investigative Study,Cell culture,406,"Rapid, poor sensitivity, some are CLIA-waived; Good sensitivity and specificity, subjective interpretation; Gold standard, pure culture for further research and development, time consuming; Retrospective, cross-reaction; ; High sensitivity and specificity for special species, potential quantification; High sensitivity and specificity, covering other pathogens, FilmArray RP EZ is CLIA-waived; Rapid and safe, good sensitivity and specificity, some are CLIA-waived",1–7 days,Y,2020-04-25
12,2020-02-25,Laboratory diagnosis of emerging human coronavirus infections – the state of the art,https://www.ncbi.nlm.nih.gov/pubmed/32196430,Emerging Microbes & Infections ,Investigative Study,monoplex,406,"Rapid, poor sensitivity, some are CLIA-waived; Good sensitivity and specificity, subjective interpretation; Gold standard, pure culture for further research and development, time consuming; Retrospective, cross-reaction; ; High sensitivity and specificity for special species, potential quantification; High sensitivity and specificity, covering other pathogens, FilmArray RP EZ is CLIA-waived; Rapid and safe, good sensitivity and specificity, some are CLIA-waived",1–8 h,Y,2020-04-25
13,2020-02-25,Laboratory diagnosis of emerging human coronavirus infections – the state of the art,https://www.ncbi.nlm.nih.gov/pubmed/32196430,Emerging Microbes & Infections ,Investigative Study,multiplex,406,"Rapid, poor sensitivity, some are CLIA-waived; Good sensitivity and specificity, subjective interpretation; Gold standard, pure culture for further research and development, time consuming; Retrospective, cross-reaction; ; High sensitivity and specificity for special species, potential quantification; High sensitivity and specificity, covering other pathogens, FilmArray RP EZ is CLIA-waived; Rapid and safe, good sensitivity and specificity, some are CLIA-waived",,,2020-04-25
14,2020-02-25,Laboratory diagnosis of emerging human coronavirus infections – the state of the art,https://www.ncbi.nlm.nih.gov/pubmed/32196430,Emerging Microbes & Infections ,Investigative Study,pan-HCoV,406,High sensitivity with universal coverage of all species of HCoV,1–8 h,Y,2020-04-25
15,2020-02-25,Laboratory diagnosis of emerging human coronavirus infections – the state of the art,https://www.ncbi.nlm.nih.gov/pubmed/32196430,Emerging Microbes & Infections ,Investigative Study,Serology,406,"Rapid, poor sensitivity, some are CLIA-waived; Good sensitivity and specificity, subjective interpretation; Gold standard, pure culture for further research and development, time consuming; Retrospective, cross-reaction; ; High sensitivity and specificity for special species, potential quantification; High sensitivity and specificity, covering other pathogens, FilmArray RP EZ is CLIA-waived; Rapid and safe, good sensitivity and specificity, some are CLIA-waived",2–8 h,Y,2020-04-25
16,2020-02-25,Laboratory diagnosis of emerging human coronavirus infections – the state of the art,https://www.ncbi.nlm.nih.gov/pubmed/32196430,Emerging Microbes & Infections ,Investigative Study,specific-HCoV,406,High sensitivity with universal coverage of all species of HCoV,15-30 min,Y,2020-04-25
17,2020-02-26,"Potential Rapid Diagnostics, Vaccine and Therapeutics for 2019 Novel Coronavirus (2019-nCoV): A Systematic Review.",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7141113/,Journal of Clinical Medicine,Investigative Study,ELISA,16 studies,"Sensitivity, Specificity, positive predictive value, and negative predictive value of the test were ELISA: 98.2%, 98.7%, 98.7%,  and 98.4%",,Y,2020-04-25
18,2020-02-27,Development and clinical application of a rapid IgM‐IgG combined antibody test for SARS‐CoV‐2 infection diagnosis,https://onlinelibrary.wiley.com/doi/full/10.1002/jmv.25727,Journal of medical viriology ,Investigative Study,Serology,525,"the IgG‐IgM combined antibody test kit, has a sensitivity of 88.66% and specificity of 90.63%.",<15 minutes,?,2020-04-25
19,2020-03-03,Clinical significance of IgM and IgG test for diagnosis of highly suspected COVID-19 infection medrxiv,https://doi.org/10.1101/2020.02.28.20029025,medRxiv,Investigative Study,Serology (IgM & IgG Ab Eval),57,The positive detection rate of combination of IgM and IgG for patients with COVID-19 negative and positive nucleic acid test was 72.73% and 87.50%.,-,Y,2020-04-25
20,2020-03-05,Molecular immune pathogenesis and diagnosis of COVID-19,https://covid19search.azurewebsites.net/home/document?docid=34e2f834075da481cda9ff4d8810fcba05abd96e&query=[{%22value%22:%22Diagnostic%20COVID-19%22}],Clinical Radiology,Investigative Study,ELISA,5,The sensitivity of SARS-CoV N-based IgG ELISA (94.7%) is significantly higher than that of SARS-CoV S-based IgG ELISA (58.9%).The sensitivity of SARS-CoV-2 IgG/IgM remains to be studied.,-,Y,2020-04-25
21,2020-03-06,Serological detection of 2019-nCoV respond to the epidemic: A useful complement to nucleic acid testing medrxiv,https://www.medrxiv.org/content/10.1101/2020.03.04.20030916v2,medRxiv,Investigative Study,Serology (IgM & IgG Ab Eval),736,"IgM & IgG Sensitivity of 100%, Specificity of ~98%",>4 hrs,Y,2020-04-25
22,2020-03-11,2019 Novel Coronavirus Disease (COVID-19): Paving the Road for Rapid Detection and Point-of-Care Diagnostics,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7142866/,Micromachines,Investigative Study,Serology ,-,Serology Sensitivity 88.66%,,Y,2020-04-25
23,2020-03-26,"Report from the American Society for Microbiology COVID-19 International Summit, 23 March 2020: Value of Diagnostic Testing for SARS–CoV-2/COVID-19",https://mbio.asm.org/content/11/2/e00722-20.abstract,American society of microbiology,Investigative Study,Serology,-,-,7-11 days postexposure to virus,,2020-04-25
24,2020-03-30,Performance of VivaDiag COVID‐19 IgM/IgG Rapid Test is inadequate for diagnosis of COVID‐19 in acute patients referring to emergency room department,https://onlinelibrary-wiley-com.ezp-prod1.hul.harvard.edu/doi/full/10.1002/jmv.25800,Journal of Medical Virology,Investigative Study,VivaDiag COVID-19 IgM / IgG Rapid Test lateral flow immunoassay (LFIA),110,This study states that VivaDiag COVID‐19 IgM/IgG Rapid Test lateral flow immunoassay (LFIA) should not be used for diagnosis of COVID‐19 (n=110) since the test demonstrated poor sensitivty as measured by concomitant RT-PCR testing.,15 mins,?,2020-04-25
25,2020-04-03,The Laboratory Diagnosis of COVID-19 Infection: Current Issues and Challenges,https://jcm.asm.org/content/early/2020/04/03/JCM.00512-20.long,Journal of Clinical Microbiology,Investigative Study,Rapid antigen test ,426,-,-,Y,2020-04-25
26,2020-04-03,The Laboratory Diagnosis of COVID-19 Infection: Current Issues and Challenges,https://jcm.asm.org/content/early/2020/04/03/JCM.00512-20.long,Journal of Clinical Microbiology,Investigative Study,Serology ,426,-,-,Y,2020-04-25
27,2020-04-13,Diagnostic Testing for Severe Acute Respiratory Syndrome-Related Coronavirus-2: A Narrative Review.,https://www.ncbi.nlm.nih.gov/pubmed/32282894,Annals of Internal Medicine,Investigative Study,Antigen Detection test,-,-,>1 Hour,Y,2020-04-25
28,2020-04-13,Diagnostic Testing for Severe Acute Respiratory Syndrome-Related Coronavirus-2: A Narrative Review.,https://www.ncbi.nlm.nih.gov/pubmed/32282894,Annals of Internal Medicine,Investigative Study,"RT-PCR, Serology",-,-,>1 Hour NAAT (PCR),Y,2020-04-25
29,2020-04-13,Diagnostic Testing for Severe Acute Respiratory Syndrome-Related Coronavirus-2: A Narrative Review.,https://www.ncbi.nlm.nih.gov/pubmed/32282894,Annals of Internal Medicine,Investigative Study,Serology ,-,-,-,Y,2020-04-25
30,2020-04-17,RAPID SEROLOGICAL TESTS HAVE A ROLE IN ASYMPTOMATIC HEALTH WORKERS COVID-19 SCREENING,https://www.medrxiv.org/content/10.1101/2020.04.15.20057786v1.full.pdf,medRxiv,Investigative Study,rapid serological test Viva-Diag analyzingCOVID-19 associated-IgG/IgM.,512,"Viva-Diag is able to evidence subjects positive for IgM expression. However, discordant results with respect to rt-PCR and CLIA assays clearly refer to further studies to optimize the utilization of the serological test in asymptomatic and in at risk subjects.",-,?,2020-04-25
31,2020-04-17,The Detection of SARS-CoV-2 using the Cepheid Xpert Xpress SARS-CoV-2 and Roche cobas SARS-CoV-2 Assays,https://jcm.asm.org/content/jcm/early/2020/04/17/JCM.00772-20.full.pdf,Journal of Clinical Microbiology,Investigative Study,Roche cobas SARS-CoV-2 assay,103,Cepheid Xpert Xpress SARS-CoV-2 and Roche63 cobas SARS-CoV-2 assays show excellent agreement (>99%), Roche 3 hr 45 min,Y,2020-04-25
32,Unknown,The Detection of SARS-CoV-2 using the Cepheid Xpert Xpress SARS-CoV-2 and Roche cobas SARS-CoV-2 Assays,https://jcm.asm.org/content/jcm/early/2020/04/17/JCM.00772-20.full.pdf,Journal of Clinical Microbiology,Investigative Study,Cepheid Xpert Xpress SARS-CoV-2 assay,103,Cepheid Xpert Xpress SARS-CoV-2 and Roche63 cobas SARS-CoV-2 assays show excellent agreement (>99%),45 mins,Y ,2020-04-25
33,Unknown,Geospatial Hotspots Need Point-of-Care Strategies to Stop Highly Infectious Outbreaks: Ebola and Coronavirus.,https://www.ncbi.nlm.nih.gov/pubmed/32298139,Arch Pathol Lab Med,Investigative Study,Serology ,136 studies,-,-,Y,2020-04-25
